

## **“Accurate PH Diagnosis and Classification for Treatment”**

### **Faculty and Planning Committee Disclosures**

1. **Jessica B. Badlam, MD**, has no financial relationships to disclose.
2. **Murali M. Chakinala, MD**, has served as a consultant, advisor or steering committee member and/or has received grant support from Janssen Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals LLC, Express Scripts Holding Company, Acceleron Pharma, Inc., United Therapeutics Corporation, V-wave, Vaderis, Aerovate, Gossamer, Phase Bio, Gossamer, Johnson & Johnson, Liquidia Technologies, Medtronic, Complexa, Altavant, Tio Health Analytics, and Reata.
3. **Teresa De Marco, MD**, has served as a consultant, advisor or steering committee member and/or has received grant support from Acceleron Pharma, Inc., Actelion Pharmaceuticals Ltd., Johnson & Johnson, Liquidia Technologies, Altavant, Scios-Bial, United Therapeutics Corporation.
4. **Jean M. Elwing, MD**, has been a consultant, advisor or steering committee member, and/or has received grant support from Acceleron Pharma, Inc., Actelion Pharmaceuticals Ltd., Altavant, Bayer HealthCare Pharmaceuticals LLC, Complexa, Gossamer Bio, Liquidia Technologies, Phase Bio, Reata Pharmaceuticals, Inc., and United Therapeutics Corporation.
5. **Robert P. Frantz, MD**, is a consultant, advisor or steering committee member and/or has received grant support from Acceleron Pharma, Inc., Bayer HealthCare Pharmaceuticals LLC, Janssen Pharmaceuticals, Inc., Liquidia Technologies, Medtronic, United Therapeutics Corporation and UpToDate, Inc.
6. **Kristin Highland, MD**, has served as a consultant, advisor or steering committee member, speaker and/or has received grant support from Actelion Pharmaceuticals, Ltd., Acceleron Pharma, Inc., Bayer HealthCare Pharmaceuticals LLC, Boehringer Ingelheim, Eiger BioPharmaceuticals, Inc., Gossamer, Viela and United Therapeutics Corporation.
7. **Elizabeth Joseloff, PhD**, has no financial relationships to disclose.
8. **Edward Kirkpatrick, DO**, has no financial relationships to disclose.
9. **Alexandra Laughlin, MPH**, has no financial relationships to disclose.
10. **Deborah Jo Levine, MD**, has no financial relationships to disclose.
11. **Michael Mathier, MD**, has no financial relationships to disclose.
12. **Lana Melendres-Groves, MD**, has served as a consultant, advisory board member or steering committee member and/or speaker for Actelion Pharmaceuticals Ltd., Janssen Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals LLC, and United Therapeutics Corporation.
13. **Ronald Oudiz, MD**, has served as a consultant, advisory board member or steering committee member, speaker and/or has received grant support from Acceleron Pharma, Inc., Actelion Pharmaceuticals Ltd., Arena Pharmaceuticals, Inc., Gilead Sciences, Inc., Gossamer Bio, Insmmed, Liquidia, Medtronic, Respira, United Therapeutics, V-Wave; Johnson & Johnson, and AADI.
14. **Oksana A. Shlobin, MD**, has served as a consultant, advisory board member or steering committee member for Acceleron Pharma, Inc., Bayer HealthCare Pharmaceuticals LLC, United Therapeutics Corporation, and Johnson & Johnson.
15. **Elise Whalen, MSN, APRN, FNP-C, CPN**, has no financial relationships to disclose.
16. **Delphine Yung, MD**, has received grant support for clinical research from Janssen.